BioSpace News Archive

The Phase 1/2/3 trial will study the efficacy, safety, and immunogenicity of ImmunityBio’s T-Cell COVID-19 vaccine as a boost in participants who have already received a spike-only antibody-based vaccine.

Virometix today announces publication of key non-clinical proof-of-concept data on its lead vaccine candidate V-306 in two high quality peer-reviewed journals.

Ampio Pharmaceuticals today announced it will host a conference call to discuss financial results for the quarter ended June 30, 2021 , and provide a corporate business update on Wednesday, August 4, 2021, at 4:30 pm EDT/ 2:30 pm MT.

CoapTech, Inc, a medical device company focused on delivering transformative solutions for minimally-invasive surgery, announced today it has received CE Mark certification, as well as an approved CPT Procedure Code for its PUMA-G System,

The Society for Immunotherapy of Cancer (SITC) is pleased to announce the publication of a clinical practice guideline focusing on management of the toxicities called immune-related adverse events that can affect cancer patients treated with immune checkpoint inhibitors (ICIs).

Tidal Medical Technologies today announced that the U.S. Food and Drug Administration (FDA) has issued Emergency Use Authorization (EUA) for emergency use of the InSee incentive spirometer accessory for quantitatively tracking patient usage of Vyaire Medical’s AirLife incentive spirometer, as an aid in treatment of respiratory conditions by patients with Coronavirus Disease 2019 (COVID-19) in hospital settings.

OM1, a leading real-world data, outcomes and technology company with a focus on chronic diseases, today announced the launch of its multiple sclerosis (MS) registry.

Sirnaomics, Inc., a biopharmaceutical company engaged in the discovery and development of RNAi therapeutics against cancer and fibrotic diseases, today announced dose administration for the first patient in a Phase 2 study of the company’s drug candidate, STP705, for Keloid scar prevention.

Two new studies propose the first model for diagnosing, indexing and monitoring Post-Acute Sequelae of COVID-19 (PASC), also known as long COVID or long haul COVID.

Viridian Therapeutics, Inc., a biopharmaceutical company advancing new treatments for patients suffering from serious diseases but underserved by current therapies, announced that a majority of the independent directors serving on the Company’s Board of Directors approved the grant of an option to purchase 180,000 shares of the Company’s common stock to a new employee.